Triangulating health expenditure estimates from different data sources in developing countries: the case of Pakistan's private health expenditure.

Abstract:

:This article deals with the accuracy of statistical records used for political decision making and international comparative analysis. In developing countries, even major macroeconomic indicators can include data inadequacies and methodological differences in data generation between statistical agencies. Existing data show that total health expenditure as a percentage of GDP is about 50% lower in Pakistan than in other low-income countries (LIC). To determine whether these results reflect the actual situation in Pakistan or whether they are due to statistical error, Pakistan produced National Health Accounts (NHA) for the first time in 2009 to assess health spending in 2005-6. Improved NHA estimates are also being made for 2007-8, which will be based on the following: public expenditure data published with time lags; survey results for 2007-8; and multivariate analyses of data from 2010 and 2011 surveys on health-specific out-of-pocket (OOP) expenditure, healthcare providers, non-profit institutions and census data on autonomous bodies and large hospitals. Since these data are not yet available, a best estimate of health expenditure has to be made to support policy decision making and to provide a point of comparison for future NHA results. Health expenditure data are available from different data sources and estimates have been made by applying different methods, leading to a range of health spending estimates. As a result of this diversity of estimates and data, each with its own inaccuracies or gaps, there was a clear need to triangulate the available information and to identify a best possible estimate. This article compares estimates of household health expenditure from different sources, such as the Household Integrated Economic Survey, the Family Budget Survey and National Accounts (NA). The analysis shows that health expenditure figures for Pakistan have been underestimated by both WHO and the NHA. An adjusted estimate shows OOP spending to be twice as high as previously thought. Previous per capita total health expenditure estimates ranged from $US16 to $US19. The revised estimate showed per capita total health expenditure to be $US33, based on NA data. This puts Pakistan in a different position in international comparisons, with health expenditure exceeding the level of India ($US32.5) and the average of all LIC ($US24.5). Methodological differences in estimating expenditure and the multiple and conflicting estimates might cause stakeholders to make potentially adverse or even erroneous policy decisions on the allocation of resources. Because policy makers make decisions based on the estimates provided, the provision of a best estimate, made following a review of the advantages and limitations of existing sources and methods, is key.

authors

Lorenz C

doi

10.2165/11595230-000000000-00000

subject

Has Abstract

pub_date

2012-01-01 00:00:00

pages

1-13

issue

1

eissn

1175-5652

issn

1179-1896

journal_volume

10

pub_type

杂志文章
  • Implications of a data-driven approach to treatment with growth hormone in children with growth hormone deficiency and Turner syndrome.

    abstract:BACKGROUND:Response to growth hormone (GH) therapy may vary between individual patients. Therefore the use of GH in children should be closely monitored to avoid over, under, or ineffective treatment regimens. The treatment response can be evaluated using growth prediction models. In an effort to improve the accuracy o...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-013-0030-4

    authors: Kaspers S,Ranke MB,Han D,Loftus J,Wollmann H,Lindberg A,Roelants M,Kleintjens J

    更新日期:2013-06-01 00:00:00

  • Stated Uptake of Physical Activity Rewards Programmes Among Active and Insufficiently Active Full-Time Employees.

    abstract:BACKGROUND:Employers are increasingly relying on rewards programmes in an effort to promote greater levels of activity among employees; however, if enrolment in these programmes is dominated by active employees, then they are unlikely to be a good use of resources. OBJECTIVE:This study uses a stated-preference survey ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-017-0327-9

    authors: Ozdemir S,Bilger M,Finkelstein EA

    更新日期:2017-10-01 00:00:00

  • Using Post-market Utilisation Analysis to Support Medicines Pricing Policy: An Australian Case Study of Aflibercept and Ranibizumab Use.

    abstract:OBJECTIVES:To describe how post-market utilisation analysis in Australia informs cost-effectiveness assessment and pricing decisions, using aflibercept and ranibizumab as case studies. METHODS:Pharmaceutical claims were used to identify initiators of aflibercept and ranibizumab in the year after aflibercept-listing (D...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-018-0440-4

    authors: Kemp-Casey A,Pratt N,Ramsay E,Roughead EE

    更新日期:2019-06-01 00:00:00

  • A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zea

    abstract:OBJECTIVES:Invasive pneumococcal disease (IPD), pneumonia and acute otitis media (AOM) still represent a significant medical burden in children < 5 years of age in New Zealand (NZ), with marked disparities across socio-economic and ethnic groups. This cost-effectiveness evaluation aims to compare the potential impact o...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-018-0387-5

    authors: Varghese L,Talbot L,Govender A,Zhang XH,Mungall BA

    更新日期:2018-06-01 00:00:00

  • Health Insurance in Sub-Saharan Africa: A Scoping Review of the Methods Used to Evaluate its Impact.

    abstract::We conducted a scoping review with the objective of synthesizing available literature and mapping what designs and methods have been used to evaluate health insurance reforms in sub-Saharan Africa. We systematically searched for scientific and grey literature in English and French published between 1980 and 2017 using...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-019-00499-y

    authors: Degroote S,Ridde V,De Allegri M

    更新日期:2020-12-01 00:00:00

  • A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection.

    abstract:BACKGROUND:As tuberculosis screening trends to targeting high-risk populations, knowing the cost effectiveness of such screening is vital to decision makers. OBJECTIVES:The purpose of this review was to compile cost-utility analyses evaluating latent tuberculosis infection (LTBI) screening in high-risk populations tha...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-015-0183-4

    authors: Campbell JR,Sasitharan T,Marra F

    更新日期:2015-08-01 00:00:00

  • Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.

    abstract:BACKGROUND:Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Little is known about the economic burden associated with PAH patients in the US. OBJECTIVES:The objective of this study was to estimate excess direct costs associated with privately insured PAH patients in the US. METHODS:From a privately ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/11592430-000000000-00000

    authors: Kirson NY,Birnbaum HG,Ivanova JI,Waldman T,Joish V,Williamson T

    更新日期:2011-09-01 00:00:00

  • Germany's decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules.

    abstract::In Germany, the Institute for Quality and Efficiency in Health Care (IQWiG) makes recommendations for ceiling prices of drugs based on an evaluation of the relationship between costs and effectiveness. To set ceiling prices, IQWiG uses the following decision rule: the incremental cost-effectiveness ratio (ICER) of a n...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/11586640-000000000-00000

    authors: Gandjour A

    更新日期:2011-03-01 00:00:00

  • Opportunities for Use of Blockchain Technology in Medicine.

    abstract::Blockchain technology is a decentralized database that stores a registry of assets and transactions across a peer-to-peer computer network, which is secured through cryptography, and over time, its history gets locked in blocks of data that are cryptographically linked together and secured. So far, there have been use...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-018-0412-8

    authors: Radanović I,Likić R

    更新日期:2018-10-01 00:00:00

  • Financial risk of the biotech industry versus the pharmaceutical industry.

    abstract::The biotech industry now accounts for a substantial and growing proportion of total R&D spending on new medicines. However, compared with the pharmaceutical industry, the biotech industry is financially fragile. This article illustrates the financial fragility of the biotech and pharmaceutical industries in the US and...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/BF03256149

    authors: Golec J,Vernon JA

    更新日期:2009-01-01 00:00:00

  • Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications.

    abstract:BACKGROUND:Although the costs of treating inflammatory bowel disease (IBD) in developed countries are well established, they remain largely unknown in countries with recent histories of socio-economic transition including Serbia. OBJECTIVE:To estimate the costs of treatment including the resources used by patients wit...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-016-0272-z

    authors: Kostić M,Djakovic L,Šujić R,Godman B,Janković SM

    更新日期:2017-02-01 00:00:00

  • The Real-World Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Stenting in High-Risk Patients: Propensity Score-Matched Analysis of a Single-Centre Experience.

    abstract:BACKGROUND:There are limited economic evaluations comparing coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for multi-vessel coronary artery disease (MVCAD) in contemporary, routine clinical practice. OBJECTIVE:The aim was to perform a cost-effectiveness analysis comparing CABG and ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-018-0407-5

    authors: Ariyaratne TV,Ademi Z,Huq M,Rosenfeldt F,Duffy SJ,Parkinson B,Yap CH,Smith J,Billah B,Yan BP,Brennan AL,Tran L,Reid CM

    更新日期:2018-10-01 00:00:00

  • New anti-rebate legislation in South Korea.

    abstract::The South Korean Government recently announced a reform in the drug anti-rebate law, with the purpose of eradicating pervasive, unethical, and illegal rebate practices in pharmaceutical marketing. The main objective of this reform is to have the ability to bring criminal charges against doctors and pharmacists for rec...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-013-0029-x

    authors: Yu SY,Yang BM,Kim JH

    更新日期:2013-08-01 00:00:00

  • Economic Evaluations of Guideline-Based Care for Chronic Wounds: a Systematic Review.

    abstract:OBJECTIVES:The aim of this study was to review all published economic evaluations of guideline-based care for chronic wounds and to assess how useful these studies are for decision making in health services. METHODS:Embase, PubMed, Scopus, Health Technology Assessment (HTA) and National Health Service Economic Evaluat...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-018-0403-9

    authors: Cheng Q,Graves N,Pacella RE

    更新日期:2018-10-01 00:00:00

  • Inclusion of compliance and persistence in economic models: past, present and future.

    abstract::Economic models are developed to provide decision makers with information related to the real-world effectiveness of therapeutics, screening and diagnostic regimens. Although compliance with these regimens often has a significant impact on real-world clinical outcomes and costs, compliance and persistence have histori...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/BF03261872

    authors: Kadambi A,Leipold RJ,Kansal AR,Sorensen S,Getsios D

    更新日期:2012-11-01 00:00:00

  • Burning a hole in the budget: tobacco spending and its crowd-out of other goods.

    abstract::Smoking is an expensive habit. Smoking households spend, on average, more than $US1000 annually on cigarettes. When a family member quits, in addition to the former smoker's improved long-term health, families benefit because savings from reduced cigarette expenditures can be allocated to other goods. For households i...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/00148365-200403040-00009

    authors: Busch SH,Jofre-Bonet M,Falba TA,Sindelar JL

    更新日期:2004-01-01 00:00:00

  • The impact of inclusion criteria in health economic assessments.

    abstract::The debate surrounding whether the findings of efficacy studies are applicable to real-world treatment situations is ongoing. The issue of lack of applicability due to a lack of clinical heterogeneity could be addressed by employing less restrictive inclusion criteria. Given that health economic assessments based on c...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/11590150-000000000-00000

    authors: Richter A,Thieda P,Thaler K,Gartlehner G

    更新日期:2011-05-01 00:00:00

  • Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert® MTB/RIF for People Living with HIV/AIDS and People with Presumptive Multidrug-resistant Tuberculosis.

    abstract:BACKGROUND:The Xpert® MTB/RIF (Xpert) test has been shown to be effective and cost-effective for diagnosing tuberculosis (TB) under conditions with high HIV prevalence and HIV-TB co-infection but less is known about Xpert's cost in low HIV prevalence settings. Cambodia, a country with low HIV prevalence (0.7%), high TB...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-018-0397-3

    authors: Pallas SW,Courey M,Hy C,Killam WP,Warren D,Moore B

    更新日期:2018-08-01 00:00:00

  • Cost-Effectiveness of Non-Invasive and Non-Pharmacological Interventions for Low Back Pain: a Systematic Literature Review.

    abstract:BACKGROUND:Low back pain (LBP) is a major health problem, having a substantial effect on peoples' quality of life and placing a significant economic burden on healthcare systems and, more broadly, societies. Many interventions to alleviate LBP are available but their cost effectiveness is unclear. OBJECTIVES:To identi...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-016-0268-8

    authors: Andronis L,Kinghorn P,Qiao S,Whitehurst DG,Durrell S,McLeod H

    更新日期:2017-04-01 00:00:00

  • Listening to the decision makers: sustainability of PBMA in Alberta.

    abstract:BACKGROUND:Decision makers within the Calgary Health Region adopted and applied programme budgeting and marginal analysis (PBMA) for priority-setting activity across major service portfolios within the Region. METHODS:Seventeen in-depth qualitative interviews were conducted with senior managers and clinicians to gain ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/00148365-200403030-00005

    authors: Mitton C,Patten S,Donaldson C

    更新日期:2004-01-01 00:00:00

  • Curos™ Disinfection Caps for the Prevention of Infection When Using Needleless Connectors: A NICE Medical Technologies Guidance.

    abstract::Central line-associated bloodstream infections (CLABSIs) are primary, laboratory confirmed bloodstream infections in patients with a central line within 48 h of symptom onset. Catheter-related bloodstream infection (CRBSI) is a more specific term used when the cause of infection has been confirmed by catheter tip cult...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-020-00602-8

    authors: O'Connell S,Dale M,Morgan H,Carter K,Carolan-Rees G

    更新日期:2020-08-05 00:00:00

  • Effectiveness of National Pricing Policies for Patent-Protected Pharmaceuticals in the OECD: A Systematic Literature Review.

    abstract:OBJECTIVES:The aim of this review is to assess the current state of empirical research regarding the effectiveness of national pricing regulations of the patent-protected market for prescription pharmaceuticals. Effectiveness is understood to be the capacity of policies to have a desired impact on outcomes, such as hea...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-018-0437-z

    authors: Wettstein DJ,Boes S

    更新日期:2019-04-01 00:00:00

  • Ongoing pharmaceutical reforms in France: implications for key stakeholder groups.

    abstract::The rapid rise in pharmaceutical costs in France has been driven by new technologies and the growing prevalence of chronic diseases as well as considerable prescribing freedom and choice of physician among patients. This has led to the introduction of a number of reforms and initiatives in an attempt to moderate expen...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/BF03256162

    authors: Sermet C,Andrieu V,Godman B,Van Ganse E,Haycox A,Reynier JP

    更新日期:2010-01-01 00:00:00

  • Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.

    abstract:BACKGROUND:Liposomal amphotericin B (L-AMB) and amphotericin B lipid complex (ABLC) are both indicated for treating invasive fungal infections (IFIs) caused by Aspergillus, Candida and Cryptococcus spp. among patients who are refractory to or intolerant of conventional amphotericin B (CAB). Prior studies have suggested...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-013-0072-7

    authors: Yang H,Chaudhari P,Zhou ZY,Wu EQ,Patel C,Horn DL

    更新日期:2014-02-01 00:00:00

  • The impact of rural health care accessibility on cancer-related behaviors and outcomes.

    abstract:BACKGROUND:This research seeks to identify the relationship between economic factors related to the ability to receive and pay for health services and adverse cancer outcomes, as well as preventative screening and behavioral factors that influence the risk of cancer. We focus on the Northern High Plains region, where w...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-014-0099-4

    authors: Belasco EJ,Gong G,Pence B,Wilkes E

    更新日期:2014-08-01 00:00:00

  • Prescribing incentive schemes : a useful approach?

    abstract:INTRODUCTION:From 2000 to 2004, primary care organisations (PCOs) in England were legally required to operate a prescribing incentive scheme for their general practices. A statutory framework specified the types of target, maximum rewards and use of 'good cause for failure' provisions that schemes should include. Our o...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/00148365-200504020-00005

    authors: Mason AR,Drummond MF,Hunter JA,Towse AK,Cooke J

    更新日期:2005-01-01 00:00:00

  • Peristeen Transanal Irrigation System to Manage Bowel Dysfunction: A NICE Medical Technology Guidance.

    abstract::The Peristeen transanal irrigation system is intended to allow people with bowel dysfunction to flush out the lower part of the bowel as part of their bowel management strategy. Peristeen was the subject of an evaluation by the National Institute for Health and Care Excellence, through its Medical Technologies Evaluat...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-018-0447-x

    authors: Dale M,Morgan H,Carter K,White J,Carolan-Rees G

    更新日期:2019-02-01 00:00:00

  • Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.

    abstract:BACKGROUND:Treatment with antipsychotic medication is an important element of relapse prevention in the management of schizophrenia, and can reduce inpatient stays. Recently, the long-acting atypical antipsychotic paliperidone long-acting injectable (PLAI), a once-monthly LAI antipsychotic, was approved for treatment o...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-013-0050-0

    authors: Zeidler J,Mahlich J,Greiner W,Heres S

    更新日期:2013-10-01 00:00:00

  • Implementing Guidelines: The Cost and Clinical Impact of Anticoagulants in the UK Atrial Fibrillation Population.

    abstract:BACKGROUND:Updated treatment guidelines for atrial fibrillation (AF) have been released by the National Institute for Health and Care Excellence (NICE) in the UK, and highlight a current shortfall in the prescription of anticoagulants to patients with AF for stroke prevention. OBJECTIVE:To design a budget impact model...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-015-0180-7

    authors: Shields GE,Bates AE,Chapman AM

    更新日期:2015-10-01 00:00:00

  • Cost of Medicare for All: Review of the Estimates.

    abstract::This paper critically evaluates the estimates of the cost of Medicare for All (M4A) in the USA. Six studies that estimate the 1-year total cost of M4A in the USA are reviewed. These studies find that M4A would increase national health spending by as much as 16.9% or decrease it by 20.0%, representing a range of estima...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-021-00636-6

    authors: Nyman JA

    更新日期:2021-01-25 00:00:00